Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors

Therapeutic Advances in Medical Oncology

Volumn 4, Issue 5, 2012, Pages 255-270

  Kee, Damien ^a   Zalcberg, John R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

gastrointestinal stromal tumor; imatinib; resistance; sunitinib; targeted therapy; tyrosine kinase inhibitor

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; BUPARLISIB; CRENOLANIB; DASATINIB; DP 2976; DP 3636; DP 4444; EVEROLIMUS; GANETESPIB; IMATINIB; MASITINIB; MIDOSTAURIN; MOTESANIB; NILOTINIB; OLARATUMAB; PICTILISIB; PLACEBO; REGORAFENIB; RETASPIMYCIN; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VATALANIB; XL 147;

ADVANCED CANCER; ANEMIA; ARTIFICIAL EMBOLISM; ASTHENIA; BINDING AFFINITY; CANCER FATIGUE; CANCER SURVIVAL; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXON; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENE OVEREXPRESSION; GENOTYPE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IN VITRO STUDY; LONG TERM CARE; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY PERIOD; REVIEW; SIGNAL TRANSDUCTION; STEADY STATE; THYROID DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84871760899     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834012450935     Document Type: Review

References (105)

1. Agaimy A. Terracciano L.M. Dirnhofer S. Tornillo L. Foerster A. Hartmann A. et al. (2009) V600E BRAF mutations are alternative early molecular events in a subset of KIT / PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol 62: 613–616.
2. Agaram N.P. Wong G.C. Guo T. Maki R.G. Singer S. Dematteo R.P. et al. (2008) Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 47: 853–859.
3. Al-Batran S.E. Hartmann J.T. Heidel F. Stoehlmacher J. Wardelmann E. Dechow C. et al. (2007) Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer 10: 145–152.
4. Antonescu C.R. Besmer P. Guo T. Arkun K. Hom G. Koryotowski B. et al. (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Can Res 11: 4182–4190.
5. Bauer S. Duensing A. Demetri G.D. Fletcher J.A. (2007) KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene 26: 7560–7568.
6. Bauer S. Hartmann J.T. de Wit M. Lang H. Grabellus F. Antoch G. et al. (2005) Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117: 316–325.
7. Benjamin R.S. Schoffski P. Hartmann J.T. van Oosterom A. Bui B.N. Duyster J. et al. (2011) Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and KIT receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol 68: 69–77.
8. Blanke C.D. Demetri G.D. von Mehren M. Heinrich M.C. Eisenberg B. Fletcher J.A. et al. (2008 a) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26: 620–625.
9. Blanke C.D. Rankin C. Demetri G.D. Ryan C.W. von Mehren M. Benjamin R.S. et al. (2008 b) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the KIT receptor tyrosine kinase: S0033. J Clin Oncol 26: 626–632.
10. Bolton A.E. Peng B. Hubert M. Krebs-Brown A. Capdeville R. Keller U. et al. (2004) Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53: 102–106.
11. Bono P. Krause A. von Mehren M. Heinrich M.C. Blanke C.D. Dimitrijevic S. et al. (2004) Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood 103: 2929–2935.
12. Casali P.G. Joensuu H. Broto J.M. Muro X.G.D. Blay J. May C. et al. (2010) Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST). J Clin Oncol 28: 15s Abst TPS332.
13. Chapman P.B. Hauschild A. Robert C. Haanen J.B. Ascierto P. Larkin J. et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 364: 2507–2516.
14. Choi H. Charnsangavej C. de Castro Faria S. Tamm E.P. Benjamin R.S. Johnson M.M. et al. (2004) CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183: 1619–1628.
15. Corless C.L. Fletcher J.A. Heinrich M.C. (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813–3825.
16. Corless C.L. Schroeder A. Griffith D. Town A. Mcgreevey L. Harrell P. et al. (2005) Pdgfra mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23: 5357–5364.
17. Cullinane C. Natoli A. Hui Y. Conus N. Jackson S. Bruggen J. et al. (2010) Preclinical evaluation of nilotinib efficacy in an imatinib-resistant kit-driven tumor model. Mol Cancer Res 9: 1461–1468.
18. Day F.L. Desai J. Corless C.L. Heinrich M.C. Zalcberg J. (2010) Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-Igf-1R monoclonal antibody. Med Oncol: 28(Suppl. 1): S162–S164
19. Debiec-Rychter M. Cools J. Dumez H. Sciot R. Stul M. Mentens N. et al. (2005) Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKc 412 inhibitor against imatinib-resistant mutants. Gastroenterology 128: 270–279.
20. Debiec-Rychter M. Dumez H. Judson I. Wasag B. Verweij J. Brown M. et al. (2004) Use of C-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40: 689–695.
21. Debiec-Rychter M. Sciot R. Le Cesne A. Schlemmer M. Hohenberger P. van Oosterom A.T. et al. (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42: 1093–1103.
22. Dematteo R.P. Heinrich M.C. El-Rifai W.M. Demetri G. (2002) Clinical management of gastrointestinal stromal tumors: before and after Sti-571. Hum Pathol 33: 466–477.
23. Dematteo R.P. Maki R.G. Singer S. Gonen M. Brennan M.F. Antonescu C.R. (2007) Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245: 347–352.
24. Demetri G.D. Casali P.G. Blay J.Y. von Mehren M. Morgan J.A. Bertulli R. et al. (2009 a) A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Can Res 15: 5910–5916.
25. Demetri G.D. Cesne A.L. Mehren M.V. Chmielowski B. Bauer S. Chow W.A. et al. (2010) Final results from a phase III study of Ipi-504 (retaspimycin hydrochloride) versus placebo in patients (Pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. ASCO 2010 Gastrointestinal Cancers Symposium, Orlando, Florida (abstract 64).
26. Demetri G.D. George S. Abbeele A.V.D. Wagner A. Quigley M.T. Daily K. et al. (2007) Inhibition of heat shock protein 90 (HSP90) with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIS) in metastatic GIST: results of a phase I trial. ASCO 2007 Gastrointestinal cancers symposium, Orlando, Florida (abstract 12).
27. Demetri G.D. Reichardt P. Yoon-Koo K. Blay J.Y. Joensuu H. Maki R.G. et al. (2012) Randomised phase III trial of regorafenib in patients (pts) with metastatic and / or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with imatinib (IM) and sunitinib (SU): GRID trial. ASCO 2012 annual meeting, Chicago, USA (LBA10008).
28. Demetri G.D. van Oosterom A.T. Garrett C.R. Blackstein M.E. Shah M.H. Verweij J. et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329–1338.
29. Demetri G.D. Wang Y. Wehrle E. Racine A. Nikolova Z. Blanke C.D. et al. (2009 b) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable / metastatic gastrointestinal stromal tumors. J Clin Oncol 27: 3141–3147.
30. Deprimo S.E. Huang X. Blackstein M.E. Garrett C.R. Harmon C.S. Schoffski P. et al. (2009) Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Can Res 15: 5869–5877.
31. Desai J. Shankar S. Heinrich M.C. Fletcher J.A. Fletcher C.D. Manola J. et al. (2007) Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Can Res 13: 5398–5405.
32. Desai J. Yassa L. Marqusee E. George S. Frates M.C. Chen M.H. et al. (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Int Med 145: 660–664.
33. Dileo P. Randhawa R. Vansonnenberg E. Shankar S. Desai J. Morgan J.A. et al. (2004) Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (Pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM). J Clin Oncol 22(14 Suppl.): abstract 9024.
34. Eechoute K. Sparreboom A. Burger H. Franke R.M. Schiavon G. Verweij J. et al. (2011) Drug transporters and imatinib treatment: implications for clinical practice. Clin Can Res 17: 406–415.
35. Fletcher C.D. Berman J.J. Corless C. Gorstein F. Lasota J. Longley B.J. et al. (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33: 459–465.
36. Frost M.J. Ferrao P.T. Hughes T.P. Ashman L.K. (2002) Juxtamembrane mutant V560g kit is more sensitive to imatinib (STI571) compared with wild-type C-KIT whereas the kinase domain mutant D816V KIT is resistant. Mol Cancer Res 1: 1115–1124.
37. Gajiwala K.S. Wu J.C. Christensen J. Deshmukh G.D. Diehl W. Dinitto J.P. et al. (2009) KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A 106: 1542–1547.
38. Gambacorti-Passerini C. Zucchetti M. Russo D. Frapolli R. Verga M. Bungaro S. et al. (2003) Alpha 1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Can Res 9: 625–632.
39. George S. Blay J.Y. Casali P.G. Le Cesne A. Stephenson P. Deprimo S.E. et al. (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45: 1959–1968.
40. Goerres G.W. Stupp R. Barghouth G. Hany T.F. Pestalozzi B. Dizendorf E. et al. (2005) The value of PET, CT and in-line Pet / Ct in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 32: 153–162.
41. Gold J.S. van der Zwan S.M. Gonen M. Maki R.G. Singer S. Brennan M.F. et al. (2007) Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 14: 134–142.
42. Guo T. Agaram N.P. Wong G.C. Hom G. D'Adamo D. Maki R.G. et al. (2007) Sorafenib inhibits the imatinib-resistant KIT t670i gatekeeper mutation in gastrointestinal stromal tumor. Clin Can Res 13: 4874–4881.
43. Guo T. Hajdu M. Agaram N.P. Shinoda H. Veach D. Clarkson B.D. et al. (2009) Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KIT AY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Can Res 15: 6862–6870.
44. Heinrich M.C. Corless C.L. Blanke C.D. Demetri G.D. Joensuu H. Roberts P.J. et al. (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24: 476–4774.
45. Heinrich M.C. Corless C.L. Demetri G.D. Blanke C.D. von Mehren M. Joensuu H. et al. (2003 a) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342–4349.
46. Heinrich M.C. Corless C.L. Duensing A. Mcgreevey L. Chen C.J. Joseph N. et al. (2003 b) Pdgfra activating mutations in gastrointestinal stromal tumors. Science 299: 708–710.
47. Heinrich M.C. Maki R.G. Corless C.L. Antonescu C.R. Harlow A. Griffith D. et al. (2008 a) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26: 5352–5359.
48. Heinrich M.C. Owzar K. Corless C.L. Hollis D. Borden E.C. Fletcher C.D. et al. (2008 b) Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26: 5360–5367.
49. Heinrich M.C. Wise S. Hood M. Smith B. Kaufman M. Lu W. et al. (2010) In vitro activity of novel KIT / PDGFRA switch pocket kinase inhibitors against mutations associated with drug-resistant Gi stromal tumors. J Clin Oncol 28(15 Suppl.): abstract 10007.
50. Hirota S. Isozaki K. Moriyama Y. Hashimoto K. Nishida T. Ishiguro S. et al. (1998) Gain-of-function mutations of C-Kit in human gastrointestinal stromal tumors. Science 279: 577–580.
51. Infante J.R. Falchook G.S. Lawrence D.P. Weber J.S. Kefford R.F. Bendell J.C. et al. (2011) Phase I / Ii study to assess safety, pharmacokinetics, and efficacy of the oral Mek 1 / 2 inhibitor GSK 1120212 (GSK212) dosed in combination with the oral Braf inhibitor GSK 2118436 (GSK436). J Clin Oncol 29(15 Suppl.): abstract CRA8503.
52. Joensuu H. de Braud F. Grignagni G. de Pas T. Spitalieri G. Coco P. et al. (2011) Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer 104: 1686–1690.
53. Kindler H.L. Campbell N.P. Wroblewski K. Maki R.G. D'Adamo D.R. Chow W.A. et al. (2011) Sorafenib (SOR) in patients (PTS) with imatinib (IM) and sunitinib (Su)-resistant (Res) gastrointestinal stromal tumors (GIST): final results of a University of Chicago phase II consortium trial. J Clin Oncol 29(15 Suppl.): abstract 10009.
54. Kobayashi K. Szklaruk J. Trent J.C. Ensor J. Ahrar K. Wallace M.J. et al. (2009) Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors. Am J Clin Oncol 32: 574–581.
55. Larghero J. Leguay T. Mourah S. Madelaine-Chambrin I. Taksin A.L. Raffoux E. et al. (2003) Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem Pharmacol 66: 1907–1913.
56. Le Cesne A. Blay J.Y. Bui B.N. Bouche O. Adenis A. Domont J. et al. (2010) Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer 46: 1344–1351.
57. Lewis N.L. Lewis L.D. Eder J.P. Reddy N.J. Guo F. Pierce K.J. et al. (2009) Phase I study of the safety, tolerability, and pharmacokinetics of oral Cp-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol 27: 5262–5269.
58. Liegl B. Kepten I. Le C. Zhu M. Demetri G.D. Heinrich M.C. et al. (2008) Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216: 64–74.
59. Linton K.M. Taylor M.B. Radford J.A. (2006) Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. Br J Radiol 79: e40–e44.
60. Maira S. Stauffer F. Brueggen J. Furet P. Schnell C. Fritsch C. et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851–1863.
61. Maki R.G. Fletcher J.A. Heinrich M.C. Morgan J.A. George S. Desai J. et al. (2005) Results from a continuation trial of SU 11248 in patients (Pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol 23(16 Suppl.): abstract 2011.
62. Mannavola D. Coco P. Vannucchi G. Bertuelli R. Carletto M. Casali P.G. et al. (2007) A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92: 3531–3534.
63. Mcauliffe J.C. Wang W.L. Pavan G.M. Pricl S. Yang D. Chen S.S. et al. (2008) Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors. Mol Oncol 2: 161–163.
64. Meta-GIST (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 28: 1247–1253.
65. Miettinen M. Lasota J. (2006 a) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Sem Diag Path 23: 70–83.
66. Miettinen M. Lasota J. (2006 b) Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130: 1466–1478.
67. Miselli F.C. Casieri P. Negri T. Orsenigo M. Lagonigro M.S. Gronchi A. et al. (2007) C-KIT/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Clin Can Res 13: 2369–2377.
68. Montemurro M. Schoffski P. Reichardt P. Gelderblom H. Schutte J. Hartmann J.T. et al. (2009) Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 45: 2293–2297.
69. Mudan S.S. Conlon K.C. Woodruff J.M. Lewis J.J. Brennan M.F. (2000) Salvage Surgery for Patients with Recurrent Gastrointestinal Sarcoma: Prognostic Factors to Guide Patient Selection. Cancer 88: 66–74.
70. Mussi C. Ronellenfitsch U. Jakob J. Tamborini E. Reichardt P. Casali P.G. et al. (2010) Post-imatinib surgery in advanced / metastatic GIST: is it worthwhile in all patients? Ann Oncol / ESMO 21: 403–408.
71. Nishida T. Kanda T. Nishitani A. Takahashi T. Nakajima K. Ishikawa T. et al. (2008 a) Secondary mutations in the kinase domain of the kit gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci 99: 799–804.
72. Nishida T. Shirao K. Sawaki A. Koseki M. Okamura T. Ohtsu A. et al. (2008 b) Efficacy and safety profile of imatinib mesylate (STI571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase Ii study (STI571B1202). Int J Clin Oncol 13: 244–251.
73. Park S. Chapuis N. Bardet V. Tamburini J. Gallay N. Willems L. et al. (2008) PI-103, a dual inhibitor of class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22: 1698–1706.
74. Prenen H. Cools J. Mentens N. Folens C. Sciot R. Schoffski P. et al. (2006) Efficacy of the kinase inhibitor Su 11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Can Res 12: 2622–2627.
75. Prenen H. Guetens G. de Boeck G. Debiec-Rychter M. Manley P. Schoffski P. et al. (2006) Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN 107 in gastrointestinal stromal tumor cell lines. Pharmacology 77: 11–16.
76. Prior J.O. Montemurro M. Orcurto M.V. Michielin O. Luthi F. Benhattar J. et al. (2009) Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 27: 439–445.
77. Rankin C. Mehren M.V. Blanke C. Benjamin R. Fletcher C.D.M. Bramwell V. et al. (2004) Dose effect of imatinib (IM) in patients (Pts) with metastatic GIST – phase III Sarcoma Group Study S0033. J Clin Oncol 22(14 Suppl.): abstract 9005.
78. Raut C.P. Posner M. Desai J. Morgan J.A. George S. Zahrieh D. et al. (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24: 2325–2331.
79. Reichardt P. Blay J. Gelderblom H. Schlemmer M. Demetri G.D. Bui N.B. et al. (2010) Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): first results from Enest G3. J Clin Oncol 28(15 Suppl): abstract 10017.
80. Reichardt P. Montemurro M. Gelderblom H. Blay J. Rutkowski P. Bui B. et al. (2009) Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic Gist: a retrospective analysis. J Clin Oncol 27(15 Suppl.): abstract 10564.
81. Reichardt P. Pink D. Lindner T. Heinrich M.C. Cohen P.S. Wang Y. et al. (2005) A phase I / Ii trial of the oral PKC-inhibitor PKC 412 (PKC) in combination with imatinib mesylate (IM) in patients (Pts) with gastrointestinal stromal tumor (GIST) refractory to IM. J Clin Oncol 23(16 Suppl.): abstract 3016.
82. Roberts K.G. Odell A.F. Byrnes E.M. Baleato R.M. Griffith R. Lyons A.B. et al. (2007) Resistance to C-Kit kinase inhibitors conferred by V654a mutation. Mol Cancer Res 6: 1159–1166.
83. Sawaki A. Nishida T. Doi T. Yamada Y. Komatsu Y. Kanda T. et al. (2011) Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 31 March (Epub ahead of print).
84. Sawaki A. Yamada Y. Komatsu Y. Kanda T. Doi T. Koseki M. et al. (2010) Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. Cancer Chemother Pharmacol 65: 961–967.
85. Schoffski P. Reichardt P. Blay J.Y. Dumez H. Morgan J.A. Ray-Coquard I. et al. (2010) A phase I–II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol / ESMO 21: 1990–1998.
86. Serra V. Markman B. Scaltriti M. Eixhhorn P.J.A. Valero V. Guzman M. et al. (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022–8030.
87. Shah G.D. Loizos N. Youssoufian H. Schwartz J.D. Rowinsky E.K. (2010) Rationale for the development of IMC-3g3, a fully human immunoglobulin g subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha. Cancer 116: 1018–1026.
88. Shankar S. Vansonnenberg E. Desai J. Dipiro P.J. van Den Abbeele A. Demetri G.D. (2005) Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 235: 892–898.
89. Soria J.C. Massard C. Magne N. Bader T. Mansfield C.D. Blay J.Y. et al. (2009) Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and / or metastatic solid cancers. Eur J Cancer 45: 2333–2341.
90. Tarn C. Rink L. Merkel E. Flieder D. Pathak H. Koumbi D. et al. (2008) Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A 105: 8387–8392.
91. Trent J.C. Wathen K. Mehren M.V. Samuels B.L. Staddon A.P. Choy E. et al. (2011) A phase Ii study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol 29(15 Suppl): abstract 10006.
92. Trepel J. Mollapour M. Giaccone G. Neckers L. (2010) Targeting the dynamic HSP 90 complex in cancer. Nat Rev Cancer 10: 537–549.
93. Tsang J. Rudychev I. Pescatore S.L. (2006) Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (Pts) on imatinib (IM). J Clin Oncol 24(18 Suppl.) abstract 6119.
94. van Oosterom A.T. Judson I.R. Verweij J. Stroobants S. Dumez H. Donato Di Paola E. et al. (2002) Update of phase I study of imatinib (Sti571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38(Suppl. 5): S83–S87.
95. Verweij J. Casali P.G. Zalcberg J. Lecesne A. Reichardt P. Blay J.Y. et al. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364: 1127–1134.
96. Verweij J. van Oosterom A. Blay J.Y. Judson I. Rodenhuis S. van der Graaf W. et al. (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group Phase II Study. Eur J Cancer 39: 2006–2011.
97. Wagner A.J. Bendell J.C. Dolly S. Morgan J.A. Ware J.A. Fredrickson J. et al. (2011) A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J Clin Oncol 29(15 Suppl.): abstract 3020.
98. Wang Y. Trepel J.B. Neckers L.M. Giaccone G. (2010) Sta-9090, a small-molecule Hsp 90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs 11: 1466–1476.
99. Wardelmann E. Merkelbach-Bruse S. Pauls K. Thomas N. Schildhaus H.U. Heinicke T. et al. (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Can Res 12: 1743–1749.
100. Wen P.Y. Yung W.K. Lamborn K.R. Dahia P.L. Wang Y. Peng B. et al. (2006) Phase I / II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Can Res 12: 4899–4907.
101. Widmer N. Decosterd L.A. Csajka C. Montemurro M. Haouala A. Leyvraz S. et al. (2010) Imatinib plasma levels: correlation with clinical benefit in GIST patients. Br J Cancer 102: 1198–1199.
102. Wilhelm S. Chien D.S. (2002) Bay 43-9006: preclinical data. Curr Pharm Des 8: 2255–2257.
103. Wilhelm S.M. Dumas J. Adnane L. Lynch M. Carter C.A. Schutz G. et al. (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129: 245–255.
104. Yoo C. Ryu M.H. Kang B.W. Yoon S.K. Ryoo B.Y. Chang H.M. et al. (2010) Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 28: 1554–1559.
105. Zalcberg J.R. Verweij J. Casali P.G. Le Cesne A. Reichardt P. Blay J.Y. et al. (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41: 1751–1757.